AstraZeneca in deal with Galapagos; view on Seroquel law suit

15 March 2012

BioFocus and Argenta, service companies of Netherlands-based Galapagos (Euronext: GLPG), yesterday announced they have entered into a multi-year collaboration agreement with Anglo-Swedish drug major AstraZeneca (LSE: AZN) to find new compounds against key targets of interest to AstraZeneca's research programs in respiratory and inflammatory diseases.

Under the terms of the collaboration, each AstraZeneca project will engage the medicinal chemistry, biology and ADME/PK capabilities of either BioFocus or Argenta, and will also be able to access the full suite of in vivo respiratory pharmacology models which reside within Argenta. Financial details were not disclosed.

“Both BioFocus and Argenta have worked extensively with AstraZeneca over the past 10 years, and this new collaborative agreement brings enormous capability and experience to each AstraZeneca project we work on,” noted Chris Newton, senior vice president Galapagos Services.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK